
Opinion|Videos|May 29, 2024
Bispecific Antibodies Versus CAR T-Cell Therapy for RRMM in the Community Oncology Setting
Ke Ning, MD, describes similarities and differences when implementing bispecific antibodies and CAR T-cell therapy for patients with relapsed or remitting multiple myeloma in the community oncology setting.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
The Peptide Reclassification Everyone's Talking About: A Pharmacist's Take on What RFK Jr's Announcement Actually Means
2
Brain Inflammation May Not Drive Persistent Long COVID Symptoms, New Imaging Study Finds
3
Beyond Weight Loss: Exploring the Renal and Anti-Inflammatory Benefits of High-Dose Semaglutide
4
New Research Suggests Bempedoic Acid Outperforms Ezetimibe for Heart Health in Patients with Type 2 Diabetes
5








































































































































